The current relevance and use of prednisone in rheumatoid arthritis
- 9 April 2014
- journal article
- Published by Informa UK Limited in Expert Review of Clinical Immunology
- Vol. 10 (5), 557-571
- https://doi.org/10.1586/1744666x.2014.904746
Abstract
Prednisone is an old and very valuable drug in clinical use for over 60 years by now. It is well known by physicians and widely used for different kinds of inflammatory states including rheumatoid arthritis (RA). Clinical trials during the last 20 years have changed its clinical use, particularly with regards to dosage. Today, rheumatologists are treating their patients much more likely over a long period of time using a low-dose scheme. The effectiveness and safety of this low-dose use is the objective of the current clinical research and shall be enlightened in this drug profile. It is also featuring current knowledge about the value of modified-release prednisone with regards to the just published results of the 2nd Circadian Administration of Prednisone in Rheumatoid Arthritis trial. Moreover, the mechanisms of action of prednisone and its relatives will be summed up.Keywords
This publication has 92 references indexed in Scilit:
- Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)Annals Of The Rheumatic Diseases, 2012
- The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseasesArthritis & Rheumatism, 2010
- The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insightsMolecular and Cellular Endocrinology, 2010
- Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007Arthritis & Rheumatism, 2010
- Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trialAnnals Of The Rheumatic Diseases, 2008
- Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation studyAnnals Of The Rheumatic Diseases, 2008
- EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals Of The Rheumatic Diseases, 2007
- QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countriesAnnals Of The Rheumatic Diseases, 2007
- Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trialArthritis & Rheumatism, 2005
- Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor‐dependent, transcription‐independent mechanismBritish Journal of Pharmacology, 2000